By attenuating NNMT activity, 5Amino1MQ has been observed in preclinical settings to elevate NAD+ availability, enhance metabolic flux, and upregulate downstream signaling programs associated with cellular stress responses and energy expenditure (e.g., SIRT1)
"Everybody (is) lying, everyone's like, 'Oh, smaller portions,' like shut the fuck up, you're on Ozempic or one of those things," she said
Rizza S, Muniyappa R, Iantorno M, Kim JA, Chen H, Pullikotil P,
Oral GLP-1/GIP Agonist (Future) VK2735 The VENTURE-Oral trial demonstrated 12.2% weight loss at 13 weeks with an oral dual agonist formulation, potentially offering a more convenient oral option than Rybelsus if approved
Maeil Business Star Today (in Korean)